Cardiovascular effects of low versus high-dose beta-carotene in a rat model by Csépányi, Evelin et al.
Accepted Manuscript
Title: Cardiovascular effects of low versus high-dose
beta-carotene in a rat model
Author: Evelin Csepanyi Attila Czompa David Haines Istvan








Please cite this article as: Csepanyi Evelin, Czompa Attila, Haines David, Lekli
Istvan, Bakondi Edina, Balla Gyorgy, Tosaki Arpad, Bak Istvan.Cardiovascular effects
of low versus high-dose beta-carotene in a rat model.Pharmacological Research
http://dx.doi.org/10.1016/j.phrs.2015.07.021
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
1 
 
Cardiovascular effects of low versus high-dose beta-carotene in a rat model 1 
 2 
Evelin Csepanyi1, Attila Czompa1, David Haines1, Istvan Lekli1, Edina Bakondi2, Gyorgy 3 
Balla3, Arpad Tosaki1, Istvan Bak1* 4 
 5 
1University of Debrecen, Faculty of Pharmacy, Department of Pharmacology, Debrecen, 6 
Hungary 7 
2University of Debrecen, Faculty of Medicine, Department of Medical Chemistry, Debrecen, 8 
Hungary 9 
3Hemostasis, Thrombosis and Vascular Biology Research Group, Hungarian of Academy of 10 





Dr. Istvan Bak 16 
University of Debrecen, Faculty of Pharmacy, Department of Pharmacology, Bioanalytical 17 
Division, H-4032 Debrecen, Nagyerdei krt. 98., Hungary 18 
Telephone, Fax: 00-36-52-255-586 19 
E-mail: bak.istvan@pharm.unideb.hu 20 
 21 







-carotene (BC), a lipid-soluble tetraterpene precursor to vitamin A, widely distributed 27 
in plants, including many used in human diet, has well-known health-enhancing properties, 28 
including reducing risk of and treatment for certain diseases. Nevertheless, BC may also act to 29 
promote disease through the activity of BC derivatives that form in the presence of external 30 
toxicants such as cigarette smoke and endogenously-produced reactive oxygen species. The 31 
present investigation evaluates the dose-dependent cardioprotective and possibly harmful 32 
properties of BC in a rat model. Adult male rats, were gavage-fed BC for 4 weeks, at dosages 33 
of either 0, 30 or 150 mg/kg/day. Then hearts excised from the animals were mounted in a 34 
“working heart” apparatus and subjected to 30 minutes of global ischemia, followed by 120 35 
minutes of reperfusion. A panel of cardiac functional evaluations was conducted on each 36 
heart. Infarct size and total antioxidant capacity of the myocardium were assessed. Heart 37 
tissue content of heme oxygenase-1 (HO-1) by Western blot analysis; and potential direct 38 
cytotoxic effects of BC by MTT assay were evaluated. Hearts taken from rats receiving 30 39 
mg/kg/day BC exhibited significantly improved heart function at lower reperfusion times, but 40 
lost this protection at higher BC dosage and longer reperfusion times. Myocardial HO-1 41 
content was significantly elevated dose-responsively to both BC dosage. Finally, in vitro 42 
evaluation of BC on H9c2 cells showed that the agent significantly improved vitality of these 43 
cells in a dose range of 2.5-10 M. 44 
Although data presented here do not allow for a comprehensive mechanistic 45 
explanation for reduced cardioprotection at high dose BC, it is speculated that since Fe2+ 46 
produced as a metabolite of HO-1 activity, may determine whether BC acts as an antioxidant 47 
or prooxidant agent, the strong induction of this enzyme in response to ischemia/reperfusion-48 
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 53 
1. INTRODUCTION 54 
1.1 “Functional foods” in prevention of and management of chronic illness 55 
 Increasingly intensive efforts are currently being made to characterize properties of 56 
plant materials forming regular components of human diet and expand the range of their 57 
use in healthcare. Substantial ongoing increases in serious chronic diseases, particularly 58 
obesity- and lifestyle-related cardiovascular disorders and related co-morbidities, provide 59 
compelling incentive for use of natural products in healthcare – particularly in the form of 60 
“functional foods”, which are items in normal diet configured to prevent and/or mitigate 61 
disease. Such substances are increasingly attractive to healthcare providers, since they are 62 
reasonably priced compared to prescription drugs and other potentially traumatic 63 
interventions. Moreover, health-enhancing properties for many of these materials have 64 
evolved in tandem with vertebrates as mutual adaptive strategies, a process called 65 
“xenohormesis” [1]. Hence there is compelling incentive to encourage adoption of diets 66 
rich in fruits, seeds, vegetables, legumes, fish oil and other materials rich in compounds that 67 
strengthen and stabilize healthy homeostatic processes and reduce risk of cancers, 68 
cardiovascular diseases and many other chronic illnesses.  69 
 70 
-carotene: chemical and biological properties 71 
The present investigation explores the capacity of the vitamin A precursor -carotene 72 
(BC) to influence aspects of myocardial cell, tissue, and organ function that may will 73 
allow development of novel strategies for use of this compound in prevention and 74 
management of heart disease. This tetraterpene carotenoid is a 536 Da lipid-soluble plant 75 
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pigment, widely distributed in nature, including many plants regularly consumed by 76 
animals and humans [2]. It is intensely red-orange and is responsible for multi-hued 77 
coloration in many plant species; and is also used as a commercial food colorant. Many 78 
human foods contain the compound, notably yams, pumpkins and carrots. Some of its 79 
medical benefits are well established. For example, the compound has been demonstrated 80 
moderately effective as adjuvant treatment in erythropoietic protoporphyria and has 81 
additionally shown some promise also been used to reducing risk of age-related macular 82 
degeneration; and susceptibility to breast cancer risk in pre-menopausal women [3-5]. A 83 
significant cautionary note on clinical use of BC, is evidence that lung cancer risk is 84 
increased in smokers by high-dose consumption of the agent [6]. This effect is hypothesized 85 
to occur due to instability of the compound in the presence of tobacco smoke – causing its 86 
degradation to carcinogenic metabolites [7].  87 
 88 
1.3 Ischemia-reperfusion injury to cardiovascular tissue and antioxidant defense 89 
The present investigation, which evaluates cardiovascular effects of BC, is focused on 90 
processes underlying ischemia and reperfusion (I/R) injury to the myocardium. Heart disease 91 
and cardiac surgery frequently involve procedures that deprive heart tissue of oxygenated 92 
blood, resulting in ischemia, a disruption of normal tissue homeostasis. Further 93 
derangement of tissue function may occur as a result of re-oxygenation by restoration of 94 
blood flow (reperfusion), a process that triggers a burst expression in physiologic 95 
production of highly reactive oxygen-containing species during the first 5 minutes of 96 
blood reflow [8]. These compounds greatly increase oxidative stress on reperfused tissues 97 
and effects that typically include oxidation of myocardial membrane lipids resulting in 98 
impairment of cell membrane function. This oxidative stress increase is a primary cause of 99 
reperfusion-induced damage [9]. Adverse effects on cardiovascular function caused by 100 
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these processes may be counteracted by antioxidant compounds capable of scavenging 101 
oxygen-containing free radicals that are the primary agents of oxidative stress-mediated 102 
damage. Such cytoprotective agents of (mainly) plant origin produce carotenoids, notably 103 
BC, along with polyphenolic compounds and other phytochemicals such as flavonoids, 104 
anthocyanidins, proanthocyanidins and other carotenoids which have well documented 105 
benefits to cardiovascular health [10-14]. 106 
 107 
-carotene: a double-edged sword in health maintenance 108 
The effects of BC have been intensively studied and both beneficial and potentially 109 
harmful effects of the compound have been noted [6,7]. In addition to its ability to affect 110 
risk and pathogenesis of cancer, BC has been considered for use in management of heart 111 
disease based on its free radical scavenging capacities, with the cautionary note that it may 112 
also act as a tissue-damaging prooxidant – depending on the physiologic environment 113 
[15,16]. Several clinical studies can be found having investigated the cardiovascular 114 
effects of BC, but all these results are rather controversial. Most of these studies found 115 
that BC had no any benefit and may have had adverse effects on the risk of death from 116 
cardiovascular diseases mainly among smokers [17-19]. The cardioprotective value of 117 
beta carotene also appears to vary among individuals based on genetic factors. This effect 118 
is illustrated by an intriguing April 2015 report demonstrating that healthy Korean women 119 
bearing single nucleotide polymorphisms that correlate with arterial stiffening, were 120 
differentially protected by dietary supplementation with BC, along with folate and vitamin 121 
E [20]. A primary mechanism by which BC counteracts pathogenesis of cardiovascular 122 
disease, has recently been shown to result from the compound`s ability to abate 123 
atherogenic processes by inhibition of peroxidation of cardiac-associated lipids [21]. 124 
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The investigation described in the present report was undertaken to evaluate the effects 125 
of BC administration in a rat model, segregated into groups administered two different BC 126 
dosages during a 4-week period. One test group, defined as “low dose” (LD) was fed 30 127 
mg/kg/day; and a second, “high dose” (HD) group received 150 mg/kg/day, with a cohort 128 
of control (C) rats given hydroxyethyl cellulose-water vehicle. Following sacrifice at the 129 
end of the 4-week dosing period, hearts surgically excised and mounted in a “working-130 
heart” apparatus were evaluated for cardiac function parameters and tissue biomarker 131 
correlates of physiological regulation of heart activity. Potentially toxic effects of BC on 132 
cardiomyocyte function was conducted by in vitro studies of BC dosage effect on H9c2 133 
cells. The comparison of outcomes in hearts from animals treated with low-dose, high-134 
dose BC and vehicle, provided a clear perspective into how this compound affected 135 
features of heart function relevant to maintenance of healthy heart activity and treatment 136 
of disease. 137 
 138 
2. MATERIALS AND METHODS 139 
2.1 Animals 140 
The experiments were accomplished using adult male rats (Charles River 141 
Laboratories), with a body weight range of 350-400 grams. All animals received humane 142 
care in compliance with the “Principles of Laboratory Animal Care” (formulated by the 143 
U.S. National Society for Medical Research, as described in U.S. National Institutes of 144 
Health publication No. 86-23, revised 1996) and the “Guide for the Care and Use of 145 
Laboratory Animals”. Maintenance and treatment of animals used in the present study 146 
was additionally approved by the Institutional Animal Care and Use Committee of the 147 
University of Debrecen, Debrecen, Hungary. The animals were housed in wire-bottomed 148 
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cages (three rats per cage) throughout the study and were maintained on a 12:12-h light-149 
dark cycle; and provided with laboratory rodent chow pellets, and water ad libitum.  150 
 151 
2.2 Groups and administration of -carotene 152 
Rats used in the present study were segregated into 3 groups and gavage-administered 153 
the following agents: hydroxyethyl cellulose-water (1:4) vehicle control (C); LD-BC (30 154 
mg/kg/day) and HD-BC (150 mg/kg/day) suspended in hydroxyethyl cellulose-water, 155 
respectively. BC was obtained from Sigma-Aldrich Kft. (Budapest, Hungary). 156 
 157 
2.3 Ischemia-reperfusion and isolated working hearts 158 
Following 4-week treatment with vehicle or BC, the rats were anesthetized with 159 
intraperitoneal injections of ketamine-xylazine (75/10 mg/kg), with heparin anticoagulant 160 
administered intraperitoneally (1000 IU/kg). After thoracotomy, the hearts were excised 161 
and placed in ice-cold modified Krebs-Henseleit bicarbonate buffer (118.5 NaCl, 4.7 162 
KCl, 2.5 CaCl2 x H2O, 25 NaHCO3, 1.2 KH2PO4, 1.2 MgSO4, and 10.0 glucose (in mM)), 163 
then cannulated through the aorta and perfused in a Langendorff apparatus in “non-164 
working” mode (100 cm of water) for 5 minutes to flush blood out from the hearts. 165 
Subsequently, Langendorff perfusion was conducted using a cannulated pulmonary vein, 166 
during which the isolated heart preparatum was switched to working mode (at a filling 167 
pressure of 17 cm of the buffer). After 10 minutes of working perfusion, 30 minutes of 168 
global ischemia (ISA) was initiated for each procedure, by clamping the pulmonary 169 
inflow and the aortic outflow. At the end of the ischemic period, 120 minutes of 170 
reperfusion (REP) was initiated by unclamping the inflow and outflow lines. The first 10 171 
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minutes of REP was conducted in Langendorff mode to avoid the fatal ventricular 172 
arrhythmias as described [22]. 173 
 174 
2.4 Cardiac function measurements 175 
Baseline assessment of cardiac function for each isolated heart was made following 176 
10 minutes of working perfusion. To examine the recovery of the left ventricle, these 177 
parameters were measured after 30, 60, and 120 minutes of REP. Cardiac function 178 
evaluation for each experiment was conducted as previously described [22]. Briefly, heart 179 
rate (HR) was measured using a computer acquisition system (ADInstruments, 180 
PowerLab, Castle Hill, Australia); coronary flow (CF) values were obtained by timed 181 
collection of effluent draining from each heart; aortic flow (AF) measurements were 182 
made using a calibrated flow meter; cardiac output (CO) was generated as the sum of AF 183 
and CF. Stroke volume (SV) was calculated as the quotient of CO/HR [23]; and alteration 184 
in SV values, as a function of treatments, were calculated as the ratio of SV at reperfusion 185 
divided by baseline SV and multiplied by 100. 186 
 187 
2.5 Infarct size determination 188 
Estimations of infarct size (IS) were conducted using the triphenyl tetrazolium 189 
chloride (TTC) staining method as previously described [22]. Briefly, following each 30-190 
minute ISA/120-minute REP period, hearts were perfused with 50 ml 1 % (w/v) solution 191 
of TTC in phosphate buffer (pH 7.4), and the samples were stored at -70 °C for 192 
subsequent analysis. The frozen samples were sectioned, weighted, and blotted dry. The 193 
dried sections were scanned on an Epson J232D flat-bed scanner. The infarcted area 194 
(white coloration) and the risk area (entire scanned section) were measured using 195 
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planimetry software (Image J, National Institute of Health, Bethesda, Maryland, USA). 196 
Estimates of infarcted zone magnitude were subsequently obtained by multiplying 197 
infarcted areas by weight of each slice. The resulting numbers represent weight of the risk 198 
zone and the infarcted zone. Infarct size was expressed as percentage of the weight of 199 
infarcted tissue and the weight of risk zone (whole heart) [13]. 200 
 201 
2.6 Western blot analysis of heart tissue 202 
Content of HO-1 protein in the myocardium were obtained by Western blot as 203 
previously described [22]. Briefly, approximately 300 mg of left ventricular myocardial 204 
tissue were homogenized on ice using a tissue homogenizer (IKA T10 basic ULTRA-205 
TURRAX®) in isolating buffer (25 mM Tris-HCl, 25 mM NaCl, 1 mM orthovanadate, 10 206 
mM NaF, 10 mM pyrophosphate, 10 mM okadaic acid, 0.5 mM EDTA, 1 mM PMSF, 207 
and 1x protease inhibitor cocktail) and centrifuged at 2000 rpm at 4 °C for 10 minutes. 208 
The supernatants were transferred to fresh tubes and centrifuged at 10,000 rpm at 4 °C for 209 
20 minutes, after which the resulting supernatant was used as cytosolic fraction. The 210 
protein concentration was measured by ND-1000 Nano drop spectrophotometer with 211 
BCA Protein Assay Kit (Thermo Scientific, Rockford, IL). Thirty µg of protein in each 212 
sample were loaded in 10 % polyacrylamide gel and resolved using SDS-PAGE 213 
electrophoresis and then transferred to 0.45 µm pore size nitrocellulose membrane to 214 
concentrate the samples. After blocking the membranes with 7 % nonfat dry milk in 215 
TBST, membranes were incubated overnight with primary antibody solution in 1 % of 216 
nonfat dry milk in TBST (GAPDH 1/40000, antibody was obtained from Cell Signaling 217 
Technology, Boston, MA; and HO-1 1/50 was ordered from Sigma-Aldrich Kft. 218 
Budapest, Hungary) at 4 °C. Then, the membranes were washed 3 times, each for 10 219 
minutes, in TBST and incubated with horseradish peroxidase-conjugated secondary 220 
10 
 
antibody solution (Cell Signaling Technology) containing 1 % of nonfat dry milk in 221 
TBST, for two hours at room temperature. The membranes were treated with Western 222 
blot Enhanced Chemiluminescent HRP substrate (Millipore, Billerica, MA) to visualize 223 
the bands. After the Enhanced Chemiluminescent treatment, the membranes were 224 
exposed on x-ray films (Agfa, Mortsel, Belgium). The films were then digitalized by flat-225 
bed scanner (Epson J232D) and analyzed using ImageJ program and normalized the HO-226 
1 band intensities to GAPDH. 227 
 228 
2.7 MTT cell viability assays for -carotene cytotoxicity 229 
Evaluation of BC cytotoxicity on cellular survival was accomplished using the 3-(4,5-230 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previously 231 
described [24]. Briefly, H9c2 cells (ATCC, CRL-1446, LGC Standards GmbH, Wesel 232 
Germany) dissociated by trituration in medium (Dulbecco’s modified eagle’s medium 233 
from Sigma with 10% FBS, 1% penicillin-streptomycin), were seeded into 96 well plates 234 
at a density of 3000 cells/well and cultured for 1 day to establish adhesion of the wells. 235 
BC containing medium was prepared as described by Wertz et al. for keratinocyte 236 
cultures with some modifications [25]. Cells were treated with 0, 2.5, 5, 10 and 20 M 237 
BC for 4 hours, respectively. Next, following a 30-minute incubation period, half of the 238 
wells were treated with 125 µM H2O2. Four hours later addition of 20 µl MTT solution (5 239 
mg/ml in PBS) to each well and an additional 3 hours incubation at 37 °C to allow 240 
mitochondrial uptake, the medium were removed and cells were lysed by addition of 150 241 
µl of isopropanol, incubated for 15 minutes followed by measurement of absorbance at 242 
570 and 690 nm using a plate reader (FLUOstar OPTIMA, BMG Labtech). Within each 243 
experiment, absorbance values were averaged across 4 replicate wells and repeated 3 244 
times. BC cytotoxic effect assessments were estimated based on linear correlation of 245 
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absorbance values with MTT-associated H9c2 viability and reported as percentage of 246 
cells surviving 4 hours of BC exposure relative to control cells not exposed to BC. 247 
 248 
2.8 Tissue antioxidant capacity (TAC) 249 
TAC of heart tissue was measured using the CS0790-1KT antioxidant assay kit 250 
(Sigma-Aldrich Kft., BP., Hungary). Briefly, at the end of reperfusion, the hearts were 251 
frozen and stored at -70 °C until analysis. Approximately 100 mg of left ventricular 252 
myocardial tissue from each heart were homogenized in 0.5 ml of 1x Assay buffer, 253 
centrifuged at 12000 rpm, for 15 min at 4 °C and the supernatants collected for assay. 254 
Following sample preparation according to manufacturer’s instructions, the absorbance 255 
was measured at 405 nm using a plate reader (FLUOstar OPTIMA, BMG Labtech). TAC 256 
values for each heart was derived from absorbance values and expressed as Trolox 257 
equivalent (M). 258 
 259 
2.9 Statistical analysis 260 
Statistical analyses were performed using GraphPad Prism 5 software. The data are 261 
expressed as mean +/- SEM. One-way ANOVA followed by Bonferroni post-test was 262 
carried out for heart function data analysis. MTT data were compared by t-test. For 263 
Western blot and TAC data outcomes, repeated measures of one-way ANOVA followed 264 
by Tukey’s post-test was conducted. Differences were considered significant at values of 265 
P<0.05. 266 
 267 
3. RESULTS 268 
-carotene dose effects on cardiac function in isolated hearts subjected to I/R 269 
12 
 
Figure 1 shows the dose-responsive influence of 0, 30 or 150 mg/kg/day BC gavage-270 
administered to rats during a 4-week period on cardiac function in hearts isolated from 271 
the animals and subjected to 30 minutes of global ISA and 120 minutes of REP in a 272 
“working-heart” apparatus. No BC-mediated effects on AF were observed in hearts not 273 
subjected to REP, however, relative to hearts from vehicle-treated control animals, hearts 274 
from animals subjected to 30 min of ISA followed by 30 and 60 min of REP exhibited 275 
significantly increased AF when taken from rats treated with LD-BC; but interestingly, 276 
not which were subjected to 120 min of REP or from those fed with HD-BC (Figure 1A). 277 
No significant BC dosage effects on CF were observed in non-reperfused hearts, or in 278 
hearts from animals subjected to 30 min of I/R (Figure 1B). Furthermore, HD-BC 279 
treatment resulted in a significant increase on CF values after 60 and 120 min of REP 280 
relative to organs from non-BC-treated controls (P<0.05). Likewise CO in non-ISA/REP 281 
hearts and those subjected to 120 minutes of REP did not vary significantly as a result of 282 
BC treatment, whereas significant CO increases in these hearts relative to organs from 283 
non-BC-treated controls were observed in those sustaining reperfusion periods of 30 284 
minutes (P<0.05) and 60 minutes (P<0.05) from rats receiving 30 mg/kg/day BC, but not 285 
150 mg/kg/day of the agent (Figure 1C). Treatment of animals with 150 mg/kg/day BC 286 
resulted in significant increase in HR for I/R hearts (P<0.05) (Figure 1D). Evaluation of 287 
the effects of BC on heart SV, revealed no significant BC effect on this variable in non-288 
I/R hearts, or organs subjected to I/R. It was further noted that SV values in hearts 289 
receiving 30 and 60 minutes of REP from animals treated with 150 mg/kg/day BC were 290 
reduced, however it was not significant, relative to those from rats receiving low BC dose 291 
(Figure 1E). This apparent loss of cardioprotection at elevated BC dosage was further 292 
confirmed by measurement of stroke volume decline (dSV). These results demonstrated 293 
that relative to non-I/R hearts, hearts subjected to 30 and 60, but not 120 minutes of REP 294 
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exhibited lesser declines in stroke volume when taken from animals treated with 30 295 
mg/kg/day BC than from rats receiving 0 or 150 mg/kg/day BC, however it did not reach 296 
the significant level. (Figure 1F). 297 
Hearts were isolated from 3 groups of rats (n = 6 per group). Rats in each test group 298 
received hydroxyethyl cellulose-water (1:4) vehicle control (white bars); BC 30 299 
mg/kg/day (black-shaded bars); and BC 150 mg/kg/day (gray-shaded bars) and sacrificed 300 
following a 4-week time period of BC treatment. Hearts isolated from each rat were 301 
subjected to 30 minutes of global ISA followed by either 120 minutes of REP in an 302 
isolated “working-heart” apparatus to induce I/R-induced injury and evaluated for 303 
selected cardiac functions. Results are shown as average values from each group of 304 
animals ± SEM of AF (1A); CF (1B); CO (1C); HR (1D); SV (1E); and dSV (1F). 305 
*P<0.05 for comparison of the magnitude of each cardiac function measured in each test 306 
group receiving BC, relative to hearts from vehicle-treated control animals. #P<0.05 for 307 
comparison of the magnitude of cardiac function measured in LD-BC relative to hearts 308 
from HD-BC treated animals. 309 
 310 
-carotene dose effects on I/R-induced infarct zone extent and tissue antioxidant 311 
capacity 312 
The influence of BC on the extent of I/R injury-associated infarct zones is shown 313 
in Figure 2A. Macroscopic analysis of TTC solution-perfused heart sections from rats 314 
subjected to 30 minutes of global ISA followed by 120 minutes of REP in a “working-315 
heart” apparatus revealed that LD-BC treatment, correlated with significant reduction of 316 
the extent of infarcted myocardium relative to the control values (*P<0.05). This 317 
protective effect is abolished in hearts taken from animals treated with high-dose BC 318 
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(#P<0.05), moreover, the average extent of I/R-induced infarcted zones of hearts of these 319 
animals was non-significantly increased relative to hearts from rats administered vehicle 320 
only. 321 
The phenomenon of diminished BC-mediated protective effect on cardiac physiology was 322 
also dramatically illustrated in outcomes of experiments to assess contribution of the 323 
agent to tissue antioxidant capacity (TAC), a process that has evolved as a homeostatic 324 
countermeasure to oxidative stress. As shown in Figure 2B, isolated, I/R-injured working 325 
hearts taken from rats administered LD-BC, exhibited TAC values significantly in excess 326 
of vehicle-treated controls (*P<0.05) and hearts isolated from HD-BC treated animals 327 
(#P<0.05). Nevertheless, TAC values measured in hearts from animals received HD-BC 328 
were not significantly higher that hearts from control rats received vehicle. 329 
Infarct size was measured in hearts (n=4) following 120 min of REP by perfusion with 330 
triphenyl tetrazolium (TTC) solution, followed by macroscopic analysis of transverse 331 
sections of each heart. Average sizes of infarct zone for hearts in each group ±SEM are 332 
shown for each treatment group. TAC values for each tissue sample is expressed as 333 
Trolox equivalent (M) ±SEM are shown for each treatment group. *P<0.05 for 334 
comparison relative to values for hearts from vehicle-treated control (C) animals. #P<0.05 335 
for comparison relative to values for hearts from HD-BC treated animals. 336 
 337 
-carotene effects on heme oxygenase-1 (HO-1) protein expression 338 
Myocardial tissue levels of HO-1, which is a major mediator of cardiac homeostasis, 339 
were determined by Western blot analysis. As shown in Figure 3., the presence of HO-1 340 
protein was evaluated in isolated working hearts taken from control rats administered 341 
hydroxyethyl cellulose-water vehicle (C), over 4 weeks; a second test group given LD-342 
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BC; and a third group, fed with HD-BC. Hearts excised from these animals were either 343 
sham-treated (BL-baseline) (Figure 3. panel A), or I/R-injured (I/R) (Figure 3. panel B) 344 
by 30 minutes of global ISA and 120 minutes of REP. The results show that in control 345 
hearts which were not subjected to I/R (C-BL) HO-1 expression was not significantly 346 
different from non-injured hearts removed from rats receiving LD-BC (LD-BL), while 347 
high dose treatment (HD-BL) resulted in significantly increased HO-1 level (*P<0.05) 348 
(Figure 3.A). Furthermore, in hearts from non-treated animals and subjected to I/R (C-349 
I/R) we detected mild but non-significant increase of HO-1 compared to non-ischemic 350 
baseline hearts (C-BL) (Figure 3.B) while, production of HO-1 protein in I/R injured 351 
hearts from rats fed with either low-dose (LD-I/R) or high-dose BC (HD-I/R), was 352 
significantly higher compared to non-treated non-injured (C-BL) group (*P<0.05) (Figure 353 
3.B). Moreover, HO-1 expression in hearts removed from vehicle treated animals and 354 
subjected to I/R (C-I/R) was not significantly different from hearts excised from rats 355 
receiving LD-BC and subjected to I/R (LD-I/R), however, hearts from high-dose treated 356 
animals expressed significantly elevated levels of HO-1 protein relative to corresponding 357 
levels measured in vehicle-treated controls (C-I/R) (#P<0.05) (Figure 3.B). 358 
Expression of HO-1 protein in rat myocardium was measured in homogenized 359 
cardiac tissue samples from vehicle or BC treated hearts, with or without I/R injury. 360 
Western blot analyses were conducted on each tissue homogenate in triplicate and the 361 
signal intensity of resulting bands corresponding to HO-1 protein was measured using the 362 
Scion for Windows Densitometry Image program. Tissue content of each protein is 363 
shown as a ratio of arbitrary units for HO-1 protein to GAPDH signal. Data are expressed 364 
as mean ± SEM of 6 different blots. *P<0.05 for comparison of average levels of HO-1 in 365 
ventricular myocardium from BC-treated animals, versus non-ischemic control (C-BL) 366 
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hearts. # P<0.05 for comparison of average levels of HO-1 in ventricular myocardium 367 
from BC-treated animals subjected to I/R, versus I/R-injured control (C-I/R) hearts. 368 
 369 
3.4 MTT assay-based evaluation of -carotene cytotoxicity 370 
To determine if the significant loss of cardioprotective capacity of BC when 371 
administered at the levels defined as “high-dose” in the present study, experiments were 372 
carried out to evaluate cytotoxicity of the agent in rat H9c2 cardiomyoblasts, an in vitro 373 
model, which along with the MTT cell viability assay, has proven to be a highly versatile 374 
tool for use in cardiovascular pharmacology [26]. As shown in Figure 4., significant 375 
increases in H9c2 cell viability was observed in cultures of these cells grown 24 hours in 376 
Dulbecco’s medium supplemented with 2.5, 5 and 10 M BC, relative to cells grown 377 
with no BC added (*P<0.05). Furthermore, this protective effect was not observed in 378 
cells treated with 20 M of BC. 379 
Evaluation of BC cytotoxicity on cellular survival was accomplished using the MTT 380 
assay. H9c2 cells grown 24 hours in Dulbecco’s modified eagle’s medium and treated 381 
with 0, 2.5, 5, 10 and 20 M BC, were followed by 4-hour treatments with 125 µM H2O2 382 
and 5 mg/ml MTT reagent, lysis of cells and measurement of absorbance was at 570- and 383 
690 nm. Absorbance values were averaged across 4 replicate wells, and repeated 3 times. 384 
Outcomes are shown as average percentage of cell viability for each BC dosage level, 385 
relative to control cultures not BC-treated. *P<0.05 for comparison of average % viability 386 
versus non BC-treated cultures. 387 
 388 
4. DISCUSSION 389 
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Outcomes of the present study contribute to emerging insight into how widely 390 
available plant materials may be used to enhance strategies for maintenance of 391 
cardiovascular health and develop novel therapeutic approaches. Here, the capacity of -392 
carotene is evaluated for its ability to alter processes resulting in reduced tissue 393 
oxygenation, leading to ischemic injury to the heart and with strong relevance to the 394 
kidneys, brain and many other organs [27]. A major finding reported here, is that 395 
increasing BC dosage of may not add to any cardiovascular benefits. Moreover, the agent 396 
may mediate – and indeed, may exacerbate existing pathological mechanisms. 397 
The efficiency and vigor with which a heart is able to maintain healthy circulation may 398 
be quantitatively described by cardiac functional measurements, in particular, AF, CF, 399 
CO, SV and dSV [28] and the ability of agents that enhance antioxidant signaling to 400 
improve these functions in isolated ischemic/reperfused rat hearts has previously been 401 
demonstrated [29]. Accordingly, the significant LD-BC-mediated improvement in AF 402 
(Figure 1A), CO (Figure 1C), were not unexpected. Nevertheless, the apparent abolition 403 
or mitigation of these protective effects against I/R injury in rats treated with BC at the 404 
higher dose is intriguing. 405 
The rat model was selected for the present investigation based on the well-known 406 
features of this animal`s physiology its widespread use in cardiovascular research [30] , 407 
and extensive use of these animals in previous cardiac-related drug discovery and basic 408 
scientific work by authors of this report [10,11,13,22,31,32]. The experiments described 409 
here, were nevertheless undertaken in the context of known limitations on the 410 
translational value of carotenoid research using rat data. A significant consideration in 411 
studies such as the present one, is that although rats and mice readily convert BC to 412 
vitamin A, bioavailability of carotenoids through gut absorption is very low, requiring 413 
administration of supraphysiologic BC dosages – greatly in excess of levels from any 414 
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natural source [33]. The experiments were designed to partly offset this limitation by 415 
administration of BC in a high dose range for all conditions. Accordingly, use of these 416 
outcomes and findings in design of improved human healthcare strategies must be made 417 
conservatively, taking into account experimental versus normal dietary or therapeutic 418 
dose ranges. In the present study, even the lowest dose of BC administered to rats is very 419 
high, equivalent to more than 2 g/day/70 kg man. On a daily basis, a normal human diet 420 
may contain 3 orders of magnitude less BC [34]. The degree of translational value that 421 
these findings have for managing cardiovascular disease, will require human nutritional 422 
studies – for which the present study provides a guide to major outcomes that might be 423 
evaluated. Here it is important to emphasize the value of human, versus extended animal 424 
studies. No single animal model completely replicates BC absorption and metabolism of 425 
humans [33]. Moreover, since the present study was designed to obtain mostly qualitative 426 
evaluations of low-, versus high-dose BC effects on major cardiac parameters, no attempt 427 
was made to determine precise rat-to-human dose equivalents. Thus, human clinical 428 
evaluations of the effects described here, constitute appropriate and easily accomplished 429 
follow-on studies. 430 
Although data presented here do not allow a comprehensive mechanistic analysis, the 431 
observation that low-dose-mediated improvement of AF and CO observed at 30 and 60, 432 
but not 120 minutes of post-ischemic REP suggest that BC at the lower dosage is 433 
effectively quenching oxidative stress-promoting prooxidant compounds produced by 434 
cardiac tissue as a consequence of inflammatory reactions triggered by I/R-induced 435 
damage and/or otherwise counteracting adverse effect of these metabolites. If this is the 436 
case, then it is reasonable to predict that the higher levels of oxidative stress present with 437 
longer reperfusion periods, might overwhelm the quenching ability of BC, significantly 438 
diminishing the beneficial effects of the 150 mg/kg/day treatments. The relative ability of 439 
19 
 
BC to quench prooxidant molecules may also account for differences in magnitudes of 440 
myocardial infarct zones and tissue antioxidant capacity shown in Figure 2. The 441 
significantly reduced average infarct size observed in I/R-injured hearts of animals 442 
treated with LD-BC, relative those not administered the agent, is consistent with previous 443 
work by authors of the present report, demonstrating that the extent of myocardial infarct 444 
zones in I/R-injured hearts may be diminished with agents that reduce oxidative stress 445 
[13,22,35]. Accordingly, the significant LD-BC-mediated reduction of infarct size 446 
(Figure 2A) and increased TAC (Figure 2B), were not surprising. Moreover, abolition of 447 
these effects in hearts of animals treated with 150 mg/kg/day BC, would be expected if 448 
the quenching ability of the molecule were suppressed at a higher dose, allowing a more 449 
prooxidant cardiac tissue environment at the higher dosage. The dose-responsively 450 
increased expression of HO-1 by myocardial tissue observed for both BC and duration of 451 
REP shown in Figure 3., further supports the possibility that BC loses quenching 452 
potential and may become prooxidant as dosage increases. HO-1 is an ubiqutous 453 
antioxidant response to a wide variety of oxidative stressors, hence it is expected that its 454 
expression would increase as a result of I/R injury [27]. 455 
It is further expected that BC acting as a protective antioxidant would not be 456 
diminished by BC also acting as a quenching agent and contributor to TAC, as shown in 457 
Figure 2B. However, if this model is accurate, BC at the elevated dose, acting to promote 458 
prooxidant tissue environments is expected to stimulate HO-1 production – which is what 459 
was observed (Figure 3.). The possibility of such a mechanism is additionally validated, 460 
by the observation that HO-1 expression in I/R-injured hearts of rats treated with high-461 
dose BC (HD-I/R) was elevated relative to production of the enzyme by hearts from rats 462 
treated with high dose BC, but not subjected to I/R injury (HD-BL) (Figure 3.), since 463 
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elevated HO-1 expression would be an expected consequence of significantly higher 464 
levels of oxidative stress present in I/R-injured tissue. 465 
This analysis is supported, albeit to a minor extent by outcomes of the in vitro assays 466 
for BC cytotoxicity on H9c2 rat myocardial cells. Outcomes of these experiments (Fig. 467 
4.) show that viability of these cells is significantly enhanced in comparison to 468 
unstimulated control cultures, by addition of BC at 2.5, 5 and 10 M, with a loss of this 469 
effect at 20 M. Although these data are insufficient on which to base definitive 470 
conclusions, the results suggest that as BC dosage is increased, the protective effect of the 471 
compound is diminished and may include deleterious properties. 472 
An explanation for apparent cardioprotective effect of BC at one selected dosage and 473 
mitigation or elimination of that protection at a higher dose is speculative based on the 474 
outcomes presented here. This notwithstanding, previous studies provide some clues as to 475 
the mechanisms that may underlie the observations in this report. It is known that free 476 
radical species of the kind responsible for oxidative stress in vertebrate tissues, react with 477 
BC to produce prooxidant degradation products, such as apo-8'-beta-carotenal, that are 478 
particularly damaging to subcellular organelles, particularly mitochondria, resulting in 479 
further disruption of the redox balance of myocardial cells, oxidation of critical proteins 480 
and exacerbation of damage caused by ischemia-reperfusion injury [15,16]. Ironically, 481 
the HO-1 expression response to oxidative stressors may also contribute to loss of 482 
cardioprotection at elevated BC dosage. This is a possibility because heme oxygenases, 483 
including HO-1, reduce oxidative stress by degrading heme produced in the tissue by red 484 
blood cell turnover to produce metabolites with cytoprotective qualities, principally 485 
biliverdin (converted rapidly into bilirubin) and subtoxic levels of carbon monoxide, 486 
which is promotes antioxidant signaling. Interestingly, although ferrous iron (Fe2+) also 487 
produced by normal HO-1 activity is a benign metabolite and readily cleared, its presence 488 
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under some physical settings determines whether BC acts as an antioxidant or prooxidant 489 
compound [36]. This property has potential consequences that are paradoxical in the 490 
context of the putative role of HO-1. Normally, increased activity of this enzyme reduces 491 
oxidative stress and protects tissues from toxic insult. In the present study, I/R injury to 492 
cardiac tissue, strongly activated HO-1, resulting in elevated levels of its metabolic 493 
products, including Fe2+. Since, as described by Andersen et al., Fe2+ enhances the 494 
prooxidant properties of BC, influences that elevate HO-1 in the presence of high BC 495 
levels, potentially overwhelm the cytoprotective effects of HO-1 and increase oxidative 496 
stress on a tissue. This conclusion is speculative and will require further analysis of BC 497 
cardiovascular effects. Such a mechanism is nevertheless consistent with the known 498 
behavior of BC in the presence of Fe2+ - and if valid, accounts for the results shown in 499 
Figure 4. Potential relevance of this finding to management of cardiovascular disease is 500 
provided by an observation that an inducer of HO-1 administered orally to human 501 
patients significantly altered serum levels of transferrin, which is the physiologic 502 
transport molecule for Fe2+ [37] indicating that aspects of iron metabolism that may also 503 
impact BC utilization may be modulated by drugs that affect HO-1 activity and possibly 504 
selective chelators of Fe2+. 505 
CONCLUSIONS: The findings described above, suggest that the level of HO-1 activity 506 
in response to I/R injury may be a critical determinant for the role of BC as either a 507 
protective agent against I/R-induced heart damage, or as a contributor to I/R-related 508 
syndromes through activation of its prooxidant properties. Validity of this model depends 509 
on the degree to which redox activities of BC may be influenced in either direction by 510 
presence of Fe2+ - which has been identified as a primary factor. Ongoing characterization 511 
of these processes is continuing by this laboratory. A particularly valuable outcome 512 
anticipated for this ongoing research initiative, is the potential for combining use of BC 513 
22 
 
with HO-1 inducers, such as the sour cherry seed extracts described by Csiki et al [37], in 514 
modulation of the clinical effects of BC. 515 
FUTURE DIRECTIONS: Current efforts by authors of this report to mitigate the 516 
cardiotoxic effects of -carotene, while retaining the cardioprotective value of this 517 
compound and also HO-1 activity, are focused on development of a novel functional food 518 
class containing whole leaf extract of Tamarindus indica L. (tamarind), which in March 519 
2015 was reported to chelate ferrous iron, with a binding constant of 1.085 mol L-1 [38]. 520 
It is predicted that Fe2+ chelation in this potency range will augment transferrin activity to 521 
the extent that the capacity of endogenous HO-1 to reduce oxidative stress will be 522 
retained, while simultaneously counteracting BC toxicity by removal of Fe2+. This 523 
conclusion is currently speculative and await outcome of ongoing studies. 524 
 525 
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Figure 2.: Effect of -carotene on infarcted zone magnitude (A) and tissue 659 
antioxidant capacity (B). 660 
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Figure 4.: In vitro (MTT) assays for -carotene cytotoxicity on H9c2 cells. 666 
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